Oxidative Medicine and Cellular Longevity / 2012 / Article / Tab 1

Review Article

Preclinical and Clinical Evidence of Antioxidant Effects of Antidepressant Agents: Implications for the Pathophysiology of Major Depressive Disorder

Table 1

Antioxidant effects of antidepressant agents: preclinical and clinical studies.

AntidepressantOxidative/Antioxidant-related effectsDrug class
In vitroAnimal modelsHuman data

Amitriptyline++TCA
Bupropion+NDRI
Citalopram+SSRI
Desipramine+TCA
DuloxetineSNRI
Escitalopram++SSRI
Fluoxetine+++SSRI
Fluvoxamine++SSRI
Imipramine++TCA
Maprotiline+TCA
Milnacipran+SNRI
Mirtazapine+NaSSA
Moclobemide+MAOI
Nefazodone+SNDRI
Nortriptyline+TCA
Paroxetine+SSRI
Reboxetine++NRI
Sertraline+SSRI
Tianeptine+SSRE
Trazodone+SARI
Venlafaxine++SNRI

MAOI: monoamine oxidase inhibitor; NaSSA: noradrenergic and specific serotonergic antidepressant; NDRI: norepinephrine-dopamine reuptake inhibitor; NRI: norepinephrine reuptake inhibitor; SARI: serotonin antagonist and reuptake inhibitor; SNDRI: serotonin-norepinephrine-dopamine reuptake inhibitor; SNRI: serotonin-norepinephrine reuptake inhibitor; SSRE: selective serotonin reuptake enhancer; SSRI: selective serotonin reuptake inhibitor; TCA: tricyclic or tetracyclic antidepressant.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.